Answers are grounded in this paper and cite their sources.
Background Optimal therapy for locally-advanced adenocarcinoma (ACA) of the esophagus has been chemoradiation followed by surgery (ChemoRT + Surgery), yet the morbidity of surgery is substantial. Computed tomography (CT)-derived body composition measures and age were used to categorize patients into perioperative surgical mortality risk groups. The survival benefit of adding surgery to ChemoRT was examined after stratification by risk group. Methods CT scans were analyzed to calculate skeletal muscle gauge (SMG). A predictive model of 90-day surgical mortality was constructed based upon age and SMG. Patients were classified into low-risk (bottom 75%) and high-risk (top 25%) groups based on their predicted probability of 90-day mortality. Log-rank tests were used to compare overall survival by treatment (ChemoRT vs ChemoRT + Surgery) in both risk groups. Results Of 330 patients with locally-advanced ACA treated with chemoradiation, 262 (79.4%) underwent ChemoRT + Surgery and 90-day postoperative mortality was 5.7%. Among 247 low-risk patients, 217 (87.9%) underwent ChemoRT + Surgery and median overall survival was longer compared to ChemoRT alone (40.6mo [95% CI 31.4, 55.5] vs. 16.8mo [95% CI 11.8, 29.3], p<0.01). Among 83 high-risk patients, 45 (54.2%) underwent ChemoRT + Surgery without a significant difference in overall survival vs ChemoRT alone (23.0mo [95% CI 14.7, 51.1] vs. 27.4mo [95% CI 17.2, 32.9], p=0.60). Conclusions Low-risk patients with esophageal ACA have a survival benefit with ChemoRT + Surgery compared to ChemoRT alone. Conversely, we did not see a survival benefit with ChemoRT + Surgery in high-risk patients. Measurement of body composition and age identify a high-risk subset of patients who may not benefit from surgery after chemoradiation.
No takes yet. Share an insight, caveat, or question.
Sanderfer et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: